ID   A375/R
AC   CVCL_IW10
DR   cancercelllines; CVCL_IW10
DR   ChEMBL-Cells; CHEMBL4296205
DR   ChEMBL-Targets; CHEMBL4296383
DR   PubChem_Cell_line; CVCL_IW10
DR   Wikidata; Q54606867
RX   PubMed=26365896;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:90295; PLX-4720 (PLX4720).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0132 ! A-375
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 05-10-23; Version: 15
//
RX   PubMed=26365896; DOI=10.1016/j.molonc.2015.08.003;
RA   Baenke F., Chaneton B., Smith M., van den Broek N., Hogan K., Tang H.-R.,
RA   Viros A., Martin M., Galbraith L., Girotti M.R., Dhomen N.,
RA   Gottlieb E., Marais R.;
RT   "Resistance to BRAF inhibitors induces glutamine dependency in
RT   melanoma cells.";
RL   Mol. Oncol. 10:73-84(2016).
//